Dr Barry Walker

Dr Barry Walker leads Aeras’ preclinical research and assay development groups in designing and supporting preclinical studies to develop products in the clinic and beyond. Dr. Walker also serves on Aeras’ Portfolio Review Committee to help drive key decisions related to specific projects and products. For 18 years prior to joining Aeras, Dr. Walker was a Principal Scientist and Principal Investigator at the National Institute of Biological Standards and Control in London, where he helped facilitate and promote advancement of potential TB vaccines along the product development pathway, successfully supporting preclinical development to Phase I clinical studies. Dr. Walker also served as a core member of the Product Development Team within the TuBerculosis Vaccine Initiative (TBVI), providing regulatory advice and recommendations to vaccine developers and manufacturers. Dr. Walker worked previously as a scientist at the Leprosy and Mycobacterial Research Laboratories at the National Institute of Medical Research in London and as the Senior Research Officer at the Department of Bacteriology at the Royal Postgraduate Medical School at the Hammersmith Hospital, in London.

Dr Walker earned his BSc and PhD at the University of Western Australia in Perth, Australia.